Device Investors Showing Some Spine
This article was originally published in Start Up
This clearly isn’t the go-go period of spine in the mid 2000s, but venture capitalists can’t ignore the enormous opportunities for companies able to treat low back pain. Elsevier’s Strategic Transactions shows that just in the last year, 26 spine or low back pain companies received private funding. To be sure, many were small rounds, some were funded with debt, and some were insider rounds trying to keep companies moving forward, but venture investors showed excitement by investing in large rounds for a select number of start-ups.
You may also be interested in...
Early Stage Devices For Rare Conditions Receive FDA Funding
An early intervention to treat scoliosis and a test for diagnosing eosinophilic esophagitis were among the innovations FDA supported Oct. 21, when it announced the recipients of 15 grants worth more than $14 million and focused on rare disease treatment.
Benvenue Medical Touts Next-Generation Treatment For Vertebral Compression Fractures
At the recent CIRCE meeting, researchers presented positive clinical data comparing Benvenue Medical Inc.’s Kiva vertebral compression fracture system versus Medtronic’s market-leading Kyphon kyphoplasty system, providing a boost for Benvenue, which is awaiting FDA 510(k) clearance of its device.
LDR’s IPO Bid, FDA OKs Give Spine Much Needed Adjustment
The spine device firm LDR filed to raise up to $69 million in an initial public offering just as it gained FDA approval for its Mobi-C cervical disc for one- and two-level indications. Device investors will keep a close watch on the IPO, as one has not been staged by a venture-backed spine start-up since 2007.